Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others.
BioLine is preparing the registration of the Unyvero™ Solution and the Unyvero™ P50 Pneumonia Application with the Russian Ministry of Health for regulatory clearance to sell the CE-marked IVD in Russia.
There is a huge unmet medical need for better pneumonia diagnostics in the region. According to the WHO, 1.5 million cases of pneumonia occur in Russia each year, of which only about 0.3 to 0.4 million are registered with the authorities. 25-33% of patients experience prolonged duration due to antibiotic resistances. Diagnosis is still poor: it is estimated that 20% of all patients diagnosed with severe flu in Russia are in fact suffering from pneumonia. Mortality from pneumonia is huge, reaching 14-20% in the elderly (≥ 60 years) and up to 25% in young children.
“This agreement marks the next step in our campaign to make the Unyvero Solution available worldwide,” said Oliver Schacht, CEO of Curetis AG. “Our contract with BioLine and the distribution agreements with ATC and Mediphos demonstrate the significant interest in the Unyvero platform well beyond our home markets in Germany, Austria and Switzerland. BioLine has convinced us with its high level of professionalism and expertise and its dedication to our innovative product line. Together, we are looking forward to growing the business in Russia, Ukraine and beyond over the next years.”
“The Unyvero Solution by Curetis has deeply impressed us not only because the cartridge-based concept covers a very broad analyte spectrum, but also is simple to use,” said Alexander Semenov, President & CEO of BioLine. “The Russian market with its high number of pneumonia cases is very attractive for Western companies but needs the right partner for rapid growth. With our presence throughout all regions of Russia and a successful track record in this tender-based market we have already built a business worth tens of millions of Euros for major IVD players in Russia. Therefore, we are convinced that our collaboration with Curetis provides an attractive growth opportunity for both companies.”
BioLine will present the Unyvero™ Solution at the Modern Diagnostics of Lung Diseases conference (Oct. 2, St. Petersburg) http://hospital.primexpo.ru/ru/events/, the XXII. National Congress on Diseases of the Respiratory System (Oct. 23-26, Moscow) http://www.pulmonology.ru/ and Russia’ biggest national healthcare exhibition, the 22th International Exhibition for Health Care, Medical Engineering and Pharmaceuticals (Dec. 3-7, Moscow) (Zdravookhraneniye-2012) http://www.zdravo-expo.ru/en/.
About the Unyvero™ System
The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.
Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.
The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second Unyvero™ application for implant & tissue infections is already in product development. Cartridges for additional indications, such as blood stream infections and tuberculosis, are in preparation.
About BioLine LLC
The BioLine group of companies is an exclusive distributor of the leading worldwide companies in fields of laboratory equipment and rehabilitational hospital furniture. BioLines’ specialization lies in complex equipment, technical support, training and consulting support for laboratories of various kinds. Having entered the market in 1992, BioLine has today subsidiary enterprises in Ukraine and a number of branch offices all over the Russian Federation: in Moscow, Ekaterinburg, Nizhni Novgorod, Rostov-on-Don, Kazan and others. As for the companies’ structure, it consists of two parts: diagnostic equipment-oriented department – BioLine and laboratory common equipment-oriented department – BioSystems. The companies’ staff counts more than 150 highly qualified specialists, passed through qualifying personnel selection and many having studied in training centers of manufacturing companies in Germany, The Netherlands, Finland and the USA.
The BioLine group of companies is a frequent participant at annual trade shows, conferences and symposiums. It often sponsors and maintains as a partner various scientific and trade events dedicated to health care improvement all over the world. The BioLine group of companies has proven as a stable and reliable partner with a broad experience in this field, with qualified staff and collaborating with leading global companies.
Petrogradskaya naberezhnaya, 36, lit. A.
197101, Saint-Petersburg, Russia
Tel./ Fax: +7 (812) 320-49-49/320-49-40
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million) and has signed global collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements for its Unyvero™ Solution. The company is based in Holzgerlingen near Stuttgart, Germany.
Oliver Schacht, CEO
71088 Holzgerlingen, Germany
Tel. +49 (0) 7031 49195-10
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia here
News-ID: 237714 • Views: 1662
More Releases from Curetis AG
Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyv …
− Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyve …
- German family firm ‘Scholz-HTIK – High Tech in Kunststoff’ has been selected by Curetis based on systematic benchmarking process - Holzgerlingen (Germany), December 4, 2012 -- Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero™ Cartridge. Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the
More Releases for BioLine
Beneficial Insects Market Overview and Outlook Report by 2026| Biobest, Bioline …
Los Angeles, United State, June 10th, 2020, - The global Beneficial Insects market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Beneficial Insects market. For instance, the market dynamics section digs deep into the
Chitosan Gel Market By Size, Share, Development 2026| ADVANCED BIOPOLYMERS, Nova …
Latest Report On Chitosan Gel Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period. The global Chitosan Gel market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the
Global Chitosan Gel Market 2018 Analysis By Key Players – Novamatrix, Bioline, …
Summary WiseGuyReports.com adds “Chitosan Gel Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database. This report provides in depth study of “Chitosan Gel Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Chitosan Gel Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as
Worldwide Chemically Competent Cells Market Players 2018- Promega, Lucigen, Taka …
Recently published market study on "Global Chemically Competent Cells Market 2018-2025" examines the performance of the Chemically Competent Cells market 2018. It encloses an in-depth Research of the Chemically Competent Cells market state and the competitive landscape globally. This report analyzes the potential of Chemically Competent Cells market in the present and the future prospects from various angles in detail. Top Manufacturers Analysis and Sellers such as - Merck KGaA, Thermo
Global Hydrothermal Autoclave Market 2018 -TechInstro, Tefic Biotech, Bioline Te …
Apex Market Reports, recently published a detailed market research study focused on the “Hydrothermal Autoclave Market” across the global, regional and country level. The report provides 360° analysis of “Hydrothermal Autoclave Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Hydrothermal Autoclave on
Global Competent Cells Market Research Report 2017 : Lucigen, Bioline, Genewiz
Qyresearchreports include new market research report "Global Competent Cells Market Research Report 2017" to its huge collection of research reports. This report on the global Competent Cells market is highly detailed, covering all the important aspects of the market. With overwhelming amount of information available on the web about the global Competent Cells market, it becomes impossible to decide what is important and what is not. Expert researchers with much market